Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at firstname.lastname@example.org.
Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect toRead More»
Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved parenteral formulation of diclofenac for acute / postoperative pain. While parenteral diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics. Key product benefits over the currently marketed product include:Read More»
Lacerta Bio is pleased to represent the opportunity to in-license an innovative, approved topical formulation of diclofenac for pain. While topical diclofenac products are available in a number of markets, our client’s formulation is clinically proven to have superior safety and efficacy characteristics. This topical diclofenac has a number of advantages over available topical diclofenacRead More»
OK, so the new One-on-One Partnering system has not had a stellar introduction.
We’re not here to complain about it, as this has been well covered on LinkedIn and elsewhere.
But our experience this past month has reminded us of three key lessons which are important in any industry.
Let’s make this as clear as we can.
Any product must have customer input and feedback during development, launch, marketing, and revision.
You can tell when a company does not include customer feedback when important features are removed, only to be returned after launch.
We see this all the time in the software / IT world.
Apps frequently change or remove features which were loved by users.
Why do companies do this?
Sometimes it is perfectly clear in their minds, and they are confident that users will adjust to the new product.
And indeed, sometimes we do. We complain and lament lost features, but we continue to use the product or service due to habit, or a lack of a better alternative, or other switching cost.
But, this does not make the overall experience for us as customers very positive in the long run.
SaaS, manufacturing plants, lawnmowers, operating systems…just about anything simply has to be tested under real-world, high volume conditions before launch.
The idea of launching first, then fixing later has crept into our society because it is easy to make quick fixes to things like software.
And it’s true that problems which do not surface under laboratory conditions will only surface during real-world conditions.
For example, the recent problems found with LightSail would never have been found if they did not actually launch and deploy it into space.
But that is quite different, since it is difficult to mimic low orbit conditions in a lab.
Our suggestion to BIO would have been to pre-launch the new Partnering system to a select number of heavy users first, or in parallel to the old system, perhaps in exchange for a free pass to BIO2016.
Frustrating a few customers is far better than frustrating many.
They’ll Kill Us on Facebook
During a recent car purchase, our dealer made an interesting point.
We have to be perfect with customer service. One bad customer experience and they’ll kill us on Facebook.
How many of us have decided not to eat at a restaurant due to one bad review? Or shopped at another store or dealer due to one bad review? Or purchased another brand due to one bad review?
In his inelegance, our dealer said something very profound.
He’s right. One bad experience (even if it’s not entirely accurate or even correct) can turn into a bad review which remains on the web essentially forever.
And it’s not just Facebook. It’s not unthinkable that a bad experience with a CRO, for example, shows up on LinkedIn.
Is that CRO aware of this?
How do they respond publicly?
How much business is lost from one single bad review, even if it’s false or inaccurate?
Now I doubt anyone will decide not to attend BIO2016 simply due to the problems with the partnering system.
In fact, we expect the partnering system for BIO2016 to be far better now that this real-world launch has taken place.
But it’s not something anyone should take for granted, especially in other markets which are far more competitive.
After all, there are many other, albeit smaller, conferences which could collectively serve a company’s purposes just fine…
But no, I don’t anticipate attendance at future conventions will drop just because of this.
See You in Philly
Regardless of all the problems, we’re still looking forward to a very busy four days in Philly.
We still have a few meeting slots open. So look for us in One-on-One if you would like to meet.
Also check your email for our annual itinerary email.
You can also follow some of the action on Twitter via #BIO2015.
Safe travels, everyone.
What follows is a true story. In 2013, we were engaged to out-license a series of Preclinical assets. One of these assets was in a therapeutic area which had very few Big Pharma participants. So, we did the obvious thing. We targeted multiple people across these Big Pharma companies around the World. One of them expressed
We just finished reading a terrific academic piece by Jack Scannell and colleagues at the University of Oxford. Entitled Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing, the authors discuss adaptive licensing in the context of historical returns on R&D in our industry. (Email us if you would like
Earlier this month, our friends at Biotech and Money published a transcript from a panel discussion at their London 2015 congress. The discussion was quite interesting, and we encourage readers to check it out. The topic for this discussion was whether or not M&A is being brought earlier and earlier into the R&D lifecycle.